Regenerative Medicine-Related Business
Cell Resources Corporation, a subsidiary of Alfresa Holdings Corporation, manufactures and stores cellular raw materials (master cells), the base of regenerative medicine products, and offers contract-based services to develop and manufacture cell products.
Regenerative medicine products are handled with living cells, and the slightest differences in the manufacturing process tend to have a significant impact on product quality. Unlike conventional pharmaceuticals, maintaining the quality of regenerative medicine products is extremely difficult and calls for seamless management of the process from cell harvesting to administration. For this reason, Cell Resources Corporation has been promoting the development of a manufacturing system with global standards of quality and reproducibility in cooperation with alliance partners in Japan and overseas, in addition to building a system to centrally provide all the functions necessary for the regenerative medicine product supply chain.
Main Business
1Master Cell Manufacturing Business
In cooperation with partner medical institutions in Japan, Cell Recourses appropriately handle the tissues and cells offered by healthy donors with their consent and manufacture cellular raw materials (master cells). The company provides these master cells to companies and research institutes that develop regenerative medicine products to reduce manufacturing processes and research and development costs and shorten the time period through the launch of the products, thereby contributing to the development of the regenerative medicine industry.
2Cell Products CMO*1 and CDMO*2 Business
Cell Resources performs contract manufacturing of cell products using cells from the patient (autologous) and from donors (allogeneic). Furthermore, it is building a service structure offering comprehensive support from development and manufacturing of regenerative medicine products to their distribution in cooperation with alliance partners in Japan and overseas, and leading research conducted in Japan and overseas to successful commercialization.
- CMO (contract manufacturing organization): An organization that performs contract manufacturing of pharmaceuticals on behalf of pharmaceutical companies.
- CDMO (contract development and manufacturing organization): An organization that provides contract services ranging from development of manufacturing processes for pharmaceuticals to investigational drug and commercial manufacturing.
Business Strategy
Strengthen in-house configuration and relationships with alliance partners to provide all necessary functions in a centralized manner for building a total supply chain service for regenerative medicine products.
- CPC: Cell processing center
- QA: Quality assurance
- QC: Quality control